ANXA5 and breast carcinoma: The expression of ANXA5 was significantly lower in breast cancer patients than normal controls in subgroup analysis based on gender, age, menopause status, disease stage, nodal metastasis status, and molecular subtypes (all P < 0.001, Fig. 11d).